title: Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
abstract: The federal Drug Abuse Treatment Act 2000 (DATA) opened a window of opportunity for patients with the disease of addiction by providing increased access to options for treatment. Previously, only methadone maintenance, approved for use only through specially regulated clinics, was available to treat opioid addiction. DATA allows any physician choosing to take a short specialty training course and become certified to prescribe buprenorphine. Buprenorphine and buprenorphine/ naloxone (Subutex, Suboxone) can be prescribed by certified physicians in a traditional office setting to treat patients with opioid dependence. Clinical studies indicate buprenorphine maintenance is as effective as methadone maintenance in retaining patients in substance abuse treatment and reducing illicit opioid use. Sublingual buprenorphine is more effective than clonidine or clonidine/naltrexone in short-term opioid detoxification treatment. Buprenorphine provides an additional tool to treat opioid addiction and improve the quality of lives of these patients. More physicians are needed to treat patients with addiction. DATA facilitates this by removing existing barriers and increasing access to treatment.
authors.affiliation: George E. Wahlen Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT 84148, USA. christopher.stock@med.va.gov
authors.forename: Christopher
authors.initials: C
authors.lastname: Stock
authors.forename: Jason H
authors.initials: JH
authors.lastname: Shum
mesh_terms: D001682:Biological Availability; D002047:Buprenorphine / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D009292:Narcotic Antagonists / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D009292:Narcotic Antagonists; D002047:Buprenorphine